Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors

Exclusion Criteria

• •1. No pathological evidence;
• •2. Have allergic effect to this drug;
• •3. HIV antibody positive, or suffering from other acquired and congenital immune deficiency diseases, or have organ transplant history;
• •4. Neutrophil count \< 1.5 × 109 / L, platelet \< 100 × 109 / L, or hemoglobin \< 90 g /L;
• •5. Serum Cr above 1.5 times of normal reference range or Cr clearance rate \< 50 ml/min;
• •6. ALT, or AST \> 2.5 times of the normal range when no hepatic metastasis occur; or ALT, or AST \> 5 times of the normal range when hepatic metastasis exist;
• •7. Serum bilirubin \> 1.5 times of the normal range;
• •8. Fever above 38 ℃, or have active infection which can affect the clinical trials obviously;
• •9. Hypertension failed to be controlled (systolic blood pressure \> 160 mmHg or diastolic pressure \> 100 mmHg);
• •10. Obvious cardiovascular disorders (eg, myocardial infarction, superior vena cava syndrome, more than two grades heart disease, or heart disease which can increase the risk of ventricular arrhythm);
• •11. Not recover from any anticancer therapy or surgery;
• •12. Any clinical problems beyond control (such as severe mental, neurological, cardiovascular, respiratory system diseases, etc.);
• •13. Evidence of central nerve system metastasis;
• •14. Have some gastrointestinal disease which can affect the distribution, metabolism or removal of this drug;
• •15. Pregnant or breast-feeding women;
• •16. Poor compliance.